hotspot -WSS

hotspot

author：comprehensive 2025-09-30 18:16:54 - browse：8859

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

hotspot

WSS

The battle over the Brookhaven Landfill on Long Island

Weight bias in eating disorder treatment complicated by new weight loss drugs

3 hurdles to bringing medical devices to the U.S. market

Covid vaccine financial winners and losers, from Pfizer to Novavax

3 hurdles to bringing medical devices to the U.S. market

Donald Trump's relentless attacks on special counsel Jack Smith

focus

hotspot

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Decaf coffee targeted by food safety group under obscure FDA rule

Moonlake's readout produced a cash windfall. Risks remain

3 hurdles to bringing medical devices to the U.S. market

As demand for Covid shots wanes, Moderna seeks its next success

Steward Health Care has deal to sell doctor network to UnitedHealth

Trump demands the U.S. pay no more for drugs than other countries … again

Patient advocates debate FDA's accelerated approval process

Novavax promises a turnaround & Lilly roils the obesity market

Will generative AI in health care meet the fate of IBM's Dr. Watson?

focus

The science behind Janet Jackson's pregnancy at 49

Readout Newsletter: Merck, Vertex, and Viking updates

Weight bias in eating disorder treatment complicated by new weight loss drugs

Covid vaccine financial winners and losers, from Pfizer to Novavax

Death of patient in Alzheimer’s trial raises question of possible risks

CDC concerned about possible undetected monkeypox spread in U.K.

focus

focus

hotspot

entertainment